Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables - Other (2016 - 2023)

Historic Receivables - Other for Spyre Therapeutics (SYRE) over the last 7 years, with Q3 2023 value amounting to $163000.0.

  • Spyre Therapeutics' Receivables - Other changed N/A to $163000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $163000.0, marking a year-over-year change of. This contributed to the annual value of $375000.0 for FY2022, which is 5398.77% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Receivables - Other of $163000.0 as of Q3 2023.
  • In the past 5 years, Spyre Therapeutics' Receivables - Other registered a high of $1.6 million during Q2 2023, and its lowest value of $163000.0 during Q3 2023.
  • In the last 3 years, Spyre Therapeutics' Receivables - Other had a median value of $595000.0 in 2021 and averaged $723500.0.
  • Its Receivables - Other has fluctuated over the past 5 years, first crashed by 5398.77% in 2022, then plummeted by 6739.13% in 2023.
  • Spyre Therapeutics' Receivables - Other (Quarter) stood at $815000.0 in 2021, then crashed by 53.99% to $375000.0 in 2022, then crashed by 56.53% to $163000.0 in 2023.
  • Its Receivables - Other stands at $163000.0 for Q3 2023, versus $1.6 million for Q2 2023 and $330000.0 for Q1 2023.